Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behçet’s Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here